← Browse by Condition
Medical Condition

neuroendocrine tumors

Total Trials
6
Recruiting Now
6
Trial Phases
Phase 2, Phase 1, Phase 3

ClinicalMetric tracks all active clinical trials for neuroendocrine tumors sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — neuroendocrine tumors Clinical Trials

How many clinical trials are currently recruiting for neuroendocrine tumors?
ClinicalMetric currently tracks 6 actively recruiting clinical trials for neuroendocrine tumors, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 6. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for neuroendocrine tumors?
neuroendocrine tumors research spans Phase 1 (1 trial), Phase 2 (2 trials), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a neuroendocrine tumors clinical trial?
Eligibility criteria for neuroendocrine tumors trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
1
Phase 2
2
Phase 3
1
Top Sponsors
AC Camargo Cancer Center 1 trial
Peter MacCallum Cancer Centre, Australia 1 trial
National Cancer Institute (NCI) 1 trial
Abramson Cancer Center at Penn Medicine 1 trial
Sun Yat-sen University 1 trial

Recruiting Clinical Trials

NCT06472388 Phase 2
Recruiting
Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors
Enrollment
100 pts
Location
Brazil
Sponsor
AC Camargo Cancer Center
View Trial →
NCT05053854 Phase 1
Recruiting
PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine Tumours
Enrollment
24 pts
Location
Australia
Sponsor
Peter MacCallum Cancer Centre,...
View Trial →
NCT05237934
Recruiting
Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC)
Enrollment
300 pts
Location
United States
Sponsor
National Cancer Institute (NCI...
View Trial →
NCT04339036 Phase 2
Recruiting
CapTemY90 for Grade 2/3 NET Liver Metastases
Enrollment
70 pts
Location
United States
Sponsor
Abramson Cancer Center at Penn...
View Trial →
NCT06015802
Recruiting
Predictive Value of Serum and Tissue Molecular Markers and Imaging Features in the Invasiveness and Prognosis of Pituitary Neuroendocrine Tumors
Enrollment
300 pts
Location
China
Sponsor
Sun Yat-sen University
View Trial →
NCT05918302 Phase 3
Recruiting
Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.
Enrollment
170 pts
Location
Belgium, France, Ita...
Sponsor
Grupo Espanol de Tumores Neuro...
View Trial →

Related Conditions

neuroendocrine tumor grade 2 (2) progression (1) neuroendocrine tumor grade 1 (1) neuroendocrine tumor of pancreas (1) neuroendocrine tumor of the lung (1) neuroendocrine tumor carcinoid (1) carcinoma neuroendocrine (1) pituitary adenoma (1) lung neuroendocrine neoplasm (1) thymus neoplasms (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology